vTv Therapeutics Files 8-K Report

Ticker: VTVT · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1641489

Vtv Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyVtv Therapeutics Inc. (VTVT)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, financials

Related Tickers: VTVT

TL;DR

vTv Therapeutics filed an 8-K, likely containing routine disclosures or financial updates.

AI Summary

On January 13, 2025, vTv Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and the submission of Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates vTv Therapeutics Inc. is providing updates or disclosures to the SEC, which could contain important information for investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate indication of significant negative events.

Key Players & Entities

  • vTv Therapeutics Inc. (company) — Registrant
  • January 13, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • High Point, NC (location) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing by vTv Therapeutics Inc.?

The filing is primarily for Regulation FD Disclosure and the submission of Financial Statements and Exhibits.

What is the date of the earliest event reported in this 8-K?

The date of the earliest event reported is January 13, 2025.

In which state was vTv Therapeutics Inc. incorporated?

vTv Therapeutics Inc. was incorporated in Delaware.

What is the business address of vTv Therapeutics Inc.?

The business address is 3980 Premier Drive, Suite 310, High Point, NC 27265.

What is the Nasdaq ticker symbol for vTv Therapeutics Inc.?

The Nasdaq ticker symbol is VTVT.

Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-01-13 08:33:31

Key Financial Figures

  • $0.01 — stered Class A common stock, par value $0.01 per share VTVT Nasdaq Capital Market

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On January 13, 2025, vTv Therapeutics, Inc., (the "Company") posted on its website an updated slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time. This presentation may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of, Section 18 of the Exchange Act, nor shall it be deemed to be incorporated by reference in any filing under the 33 Act or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 vTv Therapeutics' Investor Presentation dated January 2025 104 Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. VTV THERAPEUTICS INC. By: /s/ Paul J. Sekhri Name: Paul J. Sekhri Title: President, Chief Executive Officer and Executive Chairperson Dated: January 13, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.